DYAX (Stock Symbol: DYAX)
DYAX- Stock Profile
|Stock Ticker (Symbol):||DYAX|
|Traded Exchange:||NASDAQ Stock Exchange|
|Average Traded Price:||$8.23|
|Average Daily Traded Volume:||1,445,200|
|Started to Trade on:||Tuesday, August 15, 2000|
Dyax Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel biotherapeutics for unmet medical needs in the United States. The company utilizes its proprietary drug discovery technology, known as phage display, to identify antibody, small protein, and peptide compounds. It markets KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Dyax Corp. also provides KALBITOR Access program, which offers treatment support service for patients with HAE and their healthcare providers. In addition, the company is developing a pipeline of 17 product candidates, including 4 product candidates in Phase III clinical trial, 4 product candidates in Phase II clinical trial, and 9 product candidates in Phase 1 clinical trial for the treatment of atherosclerosis, multiple sclerosis, and oncology diseases. Further, it provides library licenses to use its phage display libraries in connection with their internal therapeutic development programs; performs funded research for various collaborators; and offers patent licenses to other biopharmaceutical and pharmaceutical companies to use its phage display patents to discover and develop biologic compounds for use in specified fields. The company has strategic partnership agreement with Defiante Farmaceutica S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia; an agreement with CMIC Co., Ltd to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and an license and collaboration agreement with Cubist Pharmaceuticals, Inc. to develop and commercialize the formulation of ecallantide for the reduction of blood loss during surgery in North America and Europe. Dyax Corp. was founded in 1989 and is headquartered in Cambridge, Massachusetts.